The characteristics and clinical relevance of tumor fusion burden in non-EBV (+) gastric cancer with MSS

[1]  C. Sautès-Fridman,et al.  B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome , 2022, Nature Reviews Clinical Oncology.

[2]  Liguo Wang,et al.  Identification of novel prognostic biomarkers by integrating multi-omics data in gastric cancer , 2021, BMC Cancer.

[3]  Takaaki Masuda,et al.  Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer , 2021, Cancer medicine.

[4]  Jia Wei,et al.  Gene fusion neoantigens: Emerging targets for cancer immunotherapy. , 2021, Cancer letters.

[5]  Ashley J. Schulte,et al.  Genomically Complex Human Angiosarcoma and Canine Hemangiosarcoma Establish Convergent Angiogenic Transcriptional Programs Driven by Novel Gene Fusions , 2021, Molecular Cancer Research.

[6]  Yuan Yuan,et al.  Expression of PD1/PDL1 in gastric cancer at different microsatellite status and its correlation with infiltrating immune cells in the tumor microenvironment , 2021, Journal of Cancer.

[7]  Sai-Qi Wang,et al.  EBV-Positive Gastric Cancer: Current Knowledge and Future Perspectives , 2020, Frontiers in Oncology.

[8]  I. Kovalszky,et al.  Cross-testing of major molecular markers indicates distinct pathways of tumorigenesis in gastric adenocarcinomas and synchronous gastrointestinal stromal tumors , 2020, Scientific Reports.

[9]  I. Endo,et al.  The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2− Breast Cancer , 2020, Cells.

[10]  Dandan Zong,et al.  The Genomic Characteristics of ALK Fusion Positive Tumors in Chinese NSCLC Patients , 2020, Frontiers in Oncology.

[11]  F. Roviello,et al.  MSI and EBV Positive Gastric Cancer’s Subgroups and Their Link with Novel Immunotherapy , 2020, Journal of clinical medicine.

[12]  D. Halligan,et al.  Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer , 2020, Cancer Immunology Research.

[13]  R. Samstein,et al.  Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma , 2019, Clinical Cancer Research.

[14]  A. Klinakis,et al.  Targeting DNA repair in cancer: current state and novel approaches , 2019, Cellular and Molecular Life Sciences.

[15]  G. Forlani,et al.  CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine , 2019, Front. Immunol..

[16]  P. Agius,et al.  Immunogenic neoantigens derived from gene fusions stimulate T cell responses , 2019, Nature Network Boston.

[17]  D. Le,et al.  DNA repair defects and implications for immunotherapy. , 2018, The Journal of clinical investigation.

[18]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[19]  Joon-Oh Park,et al.  Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer , 2018, Nature Medicine.

[20]  Peter W. Laird,et al.  Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer , 2018, Cell.

[21]  Steven J. M. Jones,et al.  The Immune Landscape of Cancer , 2018, Immunity.

[22]  Li Ding,et al.  Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. , 2018, Cell systems.

[23]  Saijuan Chen,et al.  Identification of fusion genes and characterization of transcriptome features in T-cell acute lymphoblastic leukemia , 2017, Proceedings of the National Academy of Sciences.

[24]  Maristela L Onozato,et al.  Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer. , 2017, Cancer discovery.

[25]  Russell Bonneville,et al.  Landscape of Microsatellite Instability Across 39 Cancer Types. , 2017, JCO precision oncology.

[26]  Faraz Hach,et al.  Mutational Analysis of Gene Fusions Predicts Novel MHC Class I–Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer , 2017, Clinical Cancer Research.

[27]  H. McLeod,et al.  EBV infection and MSI status significantly influence the clinical outcomes of gastric cancer patients. , 2017, Clinica chimica acta; international journal of clinical chemistry.

[28]  Nicolai J. Birkbak,et al.  Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. , 2017, The Lancet. Oncology.

[29]  S. Elledge,et al.  Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.

[30]  Pornpimol Charoentong,et al.  Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.

[31]  C. Antonescu,et al.  Gene fusions in soft tissue tumors: Recurrent and overlapping pathogenetic themes , 2016, Genes, chromosomes & cancer.

[32]  A. Chinnaiyan,et al.  Landscape of gene fusions in epithelial cancers: seq and ye shall find , 2015, Genome Medicine.

[33]  Fátima Sánchez-Cabo,et al.  GOplot: an R package for visually combining expression data with functional analysis , 2015, Bioinform..

[34]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[35]  Yon Hui Kim,et al.  Identifying molecular drivers of gastric cancer through next-generation sequencing. , 2013, Cancer letters.

[36]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[37]  J. Lunceford,et al.  IFN- γ –related mRNA profile predicts clinical response to PD-1 blockade , 2017 .

[38]  M. Lotem,et al.  Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells , 2009, Cancer Immunology, Immunotherapy.